Merit Medical Systems (MMSI)
(Real Time Quote from BATS)
$100.36 USD
+0.80 (0.80%)
Updated Sep 23, 2024 01:50 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for Merit Medical Systems, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,257 | 1,151 | 1,075 | 964 | 995 |
Cost Of Goods | 673 | 632 | 589 | 563 | 562 |
Gross Profit | 584 | 519 | 485 | 401 | 432 |
Selling & Adminstrative & Depr. & Amort Expenses | 460 | 432 | 424 | 403 | 417 |
Income After Depreciation & Amortization | 124 | 88 | 61 | -2 | 15 |
Non-Operating Income | 4 | 1 | -2 | -2 | -1 |
Interest Expense | 16 | 6 | 5 | 10 | 12 |
Pretax Income | 112 | 83 | 54 | -13 | 2 |
Income Taxes | 18 | 8 | 5 | -3 | -3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 94 | 75 | 48 | -10 | 5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 94 | 75 | 48 | -10 | 5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 227 | 180 | 157 | 106 | 120 |
Depreciation & Amortization (Cash Flow) | 103 | 93 | 96 | 107 | 105 |
Income After Depreciation & Amortization | 124 | 88 | 61 | -2 | 15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 58.36 | 57.67 | 57.36 | 55.43 | 56.24 |
Diluted EPS Before Non-Recurring Items | 3.01 | 2.70 | 2.37 | 1.65 | 1.46 |
Diluted Net EPS (GAAP) | 1.62 | 1.29 | 0.84 | -0.18 | 0.10 |
Fiscal Year end for Merit Medical Systems, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 338.00 | 323.51 | 324.52 | 315.23 | 320.06 |
Cost Of Goods | 176.90 | 171.79 | 173.99 | 173.03 | 167.27 |
Gross Profit | 161.10 | 151.72 | 150.53 | 142.20 | 152.78 |
SG&A, R&D, and Dept/Amort Expenses | 115.15 | 115.79 | 116.92 | 107.07 | 123.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 45.95 | 35.93 | 33.61 | 35.13 | 28.81 |
Non-Operating Income | 7.58 | 6.47 | 2.83 | -0.07 | -0.23 |
Interest Expense | 7.68 | 8.05 | 4.98 | 4.84 | 3.68 |
Pretax Income | 45.84 | 34.35 | 31.47 | 30.22 | 24.90 |
Income Taxes | 10.12 | 6.11 | 3.84 | 4.39 | 4.66 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 35.73 | 28.24 | 27.63 | 25.83 | 20.25 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 35.73 | 28.24 | 27.63 | 25.83 | 20.25 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 58.74 | 58.57 | 58.39 | 58.38 | 58.47 |
Diluted EPS Before Non-Recurring Items | 0.92 | 0.77 | 0.81 | 0.75 | 0.81 |
Diluted Net EPS (GAAP) | 0.61 | 0.48 | 0.47 | 0.44 | 0.35 |